Pliant plans to submit the full outcomes from the BEACON-IPF trial for future publication. Credit: Lana Leon/Shutterstock. Pliant Therapeutics has discontinued the bexotegrast development for ...

Viatris’ presbyopia drug MR-141 (phentolamine ophthalmic solution 0.75%) has met the primary endpoint and all secondary ...

Pfizer has reported positive topline outcomes from the multicentre, open-label Phase III BASIS trial of Hympavzi.

Bio-Thera Solutions has commenced dosing in the randomised Phase III trial of the antibody-drug conjugate (ADC) BAT8006.

Neuron23 has dosed the first subject in the global Phase II NEULARK trial of NEU-411 for early Parkinson's disease (PD).

China-based MindRank’s oral glucagon-like peptide-1 receptor agonist (GLP-1RA) has achieved up to 10.5% weight loss in a ...

The multiple sclerosis (MS) disease-modifying therapy (DMT) market across the seven major markets (7MM: the US, France, ...

āshibio has commenced subject dosing in the Phase Ib trial, ANDECA-HO, assessing the humanised antibody, andecaliximab, in ...

The lead investigator is calling on more research into the drug’s safety profile and cost-effectiveness as a treatment for depression. Image credit: My Ocean Production / Shutterstock. A Parkinson’s ...

Experts at HLTH Europe discussed how to ensure patients have trust in the EHDS to ensure a successful roll-out.

Bavarian Nordic has initiated two Phase III clinical trials of its mpox vaccine, Jynneos, in pregnant and breastfeeding women ...

Kashiv has reported positive topline outcomes from the confirmatory trial of the proposed biosimilar to Novartis’ Xolair, ADL ...